Immunotherapy-mediated modulation of the gut microbiota in multiple sclerosis and associations with diet and clinical response-the effect of dimethyl fumarate therapy.

ABSTRACT:

Background

Accumulating evidence supports a role of the microbiota in health and disease, including in multiple sclerosis (MS). How MS drugs affect the microbiota and whether this is part of their mode of action is yet unknown.

Objectives

To assess how dimethyl fumarate (DMF) affects the gut microbiota and whether the microbiota is associated with clinical response or adverse events (AEs) to DMF or diet.

Design

An observational cohort study, in which the microbiota from 45 patients with relapsing-remitting MS pre-DMF initiation and following 6 months of DMF therapy, and from 47 matched healthy controls, were compared, and associations with clinical and dietary data assessed.

Data sources and methods

Microbial DNA was sequenced and analyzed using MicrobiomeAnaly

SUBMITTER: Staun-Ram E 

PROVIDER: S-EPMC11907610 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature